Oaktree Capital Management is a global asset manager that specializes in alternative investments, with a focus on credit, equity, and real estate. Its products are built from bottom-up, company-specific research to identify risk-controlled opportunities in sub-investment grade assets—such as high-yield bonds, distressed debt, senior loans, and convertible securities—and are assembled into portfolios managed for institutions seeking risk-adjusted returns. The firm differentiates itself through a long history in credit and distressed assets, a strict value-and-contrarian approach, and independence within the Brookfield Asset Management group since 2019, rather than relying on macro timing. Its goal is to deliver durable, risk-adjusted returns for institutional clients while growing assets under management within an independent Brookfield platform.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
$3.1B
Headquarters
Los Angeles, California
Founded
1995
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
401(k) Retirement Plan
Health Insurance
Wellness Program
Remote Work Options
Paid Vacation
Brookfield announced the final close of Oaktree's Asset-Backed Finance Fund at $2 billion, meeting its fundraising target. The fund attracted a globally diversified base of institutional investors, including US public pension plans and sovereign wealth funds. Oaktree's ABF strategy provides flexible capital solutions to originators across equipment leasing, transportation, consumer, real estate and infrastructure sectors. The firm has invested more than $19 billion across its broader ABF platform over two decades. The close builds on Brookfield's partnership with Oaktree, which began in 2019. ABF I complements Brookfield's asset-based finance platform, which totals more than $60 billion. Brookfield manages over $1 trillion in assets globally.
Cravath represented the underwriter in connection with the registered offering by an affiliate of Oaktree Capital Management, L.P. of $290 million of common shares of TORM plc., one of the world’s…
Eaton to acquire COL Group. DUBLIN - Intelligent power management company Eaton today announced it has signed an agreement to acquire COL Group from Oaktree's Power Opportunities strategy. COL Group is a leader in medium-voltage electrical distribution solutions, including SF[6]-free switchgear, grid automation technologies, and modular power systems. The acquisition will expand Eaton's European power distribution capabilities and manufacturing footprint, enhancing its ability to support growing customer demand across data center and utility markets. "COL Group brings complementary technologies, manufacturing capabilities and engineering expertise that will further strengthen Eaton's European power distribution platform," said Omar Zaire, president, EMEA Region, Corporate and Electrical Sector, Eaton. "The acquisition will enhance our ability to support utility and data center customers' increasing need for resilient, sustainable power infrastructure and integrated grid-to-chip power solutions." Under the terms of the agreement, Eaton will acquire COL Group for an enterprise value of €810 million [USD 923 million]. COL Group has forecasted sales of €250 million [USD 285 million] for 2027. COL Group is an industrial group with over a century of experience specializing in the development of electrical power distribution solutions. The company has approximately 400 employees and facilities in Turin, Milan, Bergamo, and Catania, Italy. The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the first quarter of 2027.
Warren buffett steps down as berkshire hathaway chairman. Renowned investor Howard Marks has announced his decision to step down as chairman of the investment firm Oaktree Capital Management. His son, Howard Marks Jr., will take over the role of chairman, signaling a new leadership era within the organization. Despite this transition, Marks will continue to serve on the board and will assume the title of chairman emeritus, allowing him to maintain a presence in strategic decisions and developments at the firm. Marks, known for his insightful market analyses and investment strategies, has played a significant role in shaping Oaktree Capital into one of the largest and most respected investment firms in the world. His decision to pass the leadership to his son reflects both a personal and professional legacy, as Howard Marks Jr. steps into a position that could further influence the firm's direction. The transition is expected to be smooth, given the father-and-son dynamic and the ongoing mentorship Marks intends to provide. Analysts speculate that the leadership change may enhance the firm's adaptability to evolving market conditions, with the younger Marks potentially bringing new perspectives aligned with contemporary investment trends. As Oaktree Capital continues to navigate a challenging investment landscape, the firm's commitment to its foundational principles under the new leadership remains a key focus, with both Marks and his son dedicated to maintaining Oaktree's reputation for excellence in investment management. Why this story matters: Leadership transitions can significantly impact a firm's strategic direction and market performance. Key takeaway: Howard Marks will become chairman emeritus while his son takes over as chairman of Oaktree Capital Management. Opposing viewpoint: Concerns may arise regarding the effectiveness of dynastic leadership in a rapidly changing investment environment.
Saol Therapeutics has secured up to $115 million in milestone-based funding from Oaktree to prepare for the commercial launch of SL1009, its investigational treatment for pyruvate dehydrogenase complex deficiency, a rare mitochondrial disease with no approved therapies. The clinical-stage pharmaceutical company filed an NDA resubmission on 30 June 2026, with the FDA setting a target action date of 30 December 2026. The financing will support launch readiness, with additional capital released upon meeting regulatory, clinical, and commercial milestones. Future funds would back lifecycle expansion of SL1009 into Congenital Lactic Acidosis and development of SL1002 for additional pain indications and spasticity. Separately, Saol received a Notice of Allowance from the USPTO for a patent covering SL1009 administration methods, anticipated to expire in 2045. The transaction closed on 11 September 2026.